Salient Visionary Publications

A Rare and Challenging Case: Infective Endocarditis and Pulmonary Hypertension in A Patient with Alagille Syndrome and Bicuspid Aortic Valve

Gulsum Bingol[1], Emre Ozmen[2], Ozge Ozden[1], Ferit Boyuk[3*], Matteo Cameli[4]

[1]Department of Cardiology , Memorial Bahçelievler Hospital, Turkey

[2]Department of Cardiology, Siirt, Siirt Training and Research Hospital, Turkey

[3]Department of Cardiology, Health Sciences University, Yedikule Chest Disease and Thoracic Surgery Training And Research Hospital, Turkey

[4]Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy

ABSTRACT

Alagille syndrome is a genetic disease with multi-organ involvement and can cause various congenital cardiac lesions. This syndrome is caused by mutations in the JAG1 and NOTCH gene pathways. As a result of these lesions, pulmonary hypertension can be seen in patients. While pulmonary hypertension is observed especially due to pulmonary valve stenosis; It may be due to various causes such as tetralogy of Fallot. Currently, pulmonary hypertension has not been reported in Alagille patients without cardiac anomalies in the literature.

Keywords: Alagille syndrome; Hypertension; Cardiac

INTRODUCTİON

Alagille syndrome is an autosomal dominant disease caused by pathogenic mutations in the JAG1 and NOTCH genes. Multiple system involvement is seen in Alagille syndrome. The most frequently involved system is the hepatobiliary system which is seen as a result of insufficiency of intrahepatic bile ducts. In addition, abnormalities can be observed in the cardiac, vascular, ocular, renal system and skeletal muscles.

Pulmonary hypertension may be present and it can be associated with congenital defects such as pulmonary valve stenosis or Fallot tetralogy.

In this case report we described aortic valve infective endocarditis in a patient with Alagille syndrome and group 1 pulmonary hypertension without any cardiac defect.

CASE REPORT

A 26-year-old young man, who was referred to us with complaints of increasing shortness of breath, fatigue, swollen legs, and low blood pressure in the last 1 month, also had a history of intermittent fever attacks and irregular antibiotic use. He was referred to the cardiology department by the nephrologist who was following him up for his chronic kidney disease, because of coagulase-negative staphylococcus growth in the blood culture.

The patient was diagnosed with Alagille syndrome when he was 1 month old and he had been on a hemodialysis program for the last 5 years after developing end-stage chronic kidney disease. In 2016, transthoracic echocardiography demonstrated elevated pulmonary artery pressure, and right heart catheterization was planned pulmonary artery pressure was measured as 67 mmHg and pulmonary vascular resistance as 27.9 Wood units. The patient was diagnosed with group 1 pulmonary hypertension and endothelin receptor antagonist monotherapy was started. Two years after the diagnosis of pulmonary hypertension, due to deterioration in functional capacity (FC 4), triple combination therapy consisting of IV epoprostenol + phosphodiesterase 5 inhibitor + endothelin receptor antagonist was started and a subclavian catheter was inserted for continuous infusion of IV epoprostenol. With this treatment strategy, improvement in the functional capacity of the patient was observed.

The patient was admitted to the cardiology ward also due to a complex underlying syndrome. On admission his temperature was 36.4°C, heart rate was 90 beats/minute, blood pressure was 80/30 mmHg and respiratory rate was 21 / minute. Oxygen saturation in room air was 98%.

He was rhytmic and had normal first and second heart sounds with a 3/6 Levine systolic murmur in the aortic focus. His lungs were clear with decreased sounds at the basis bilaterally. Bilateral pretibial edema was remarkable(++/++). Peripheral examination findings related to infective endocarditis were not observed. On inspection, the classic findings of Alagille syndrome such as the wide forehead, hypertelorism, 'basic' nose, and pointed chin were clearly observed.

Laboratory tests showed normal WBC levels, low platelet count, anemia, elevated CRP, procalcitonin, NT-proBNP, and creatine levels. Complete laboratory findings are given in Table 1.

Electrocardiogram (ECG) demonstrated sinus tachycardia and signs of left ventricular overload.

Transthoracic echocardiography(TTE) revealed dilatation of all heart chambers, severe global left ventricular hypokinesia with a left ventricular ejection fraction of 35%, severe tricuspid regurgitation with a high estimated pulmonary artery systolic pressure (71+10 mmHg)(Supplementary Video 1, Figure 1). TAPSE was measured to be 17 mm. Very eccentric aortic regurgitation was observed, which was not seen on previous echocardiograms, but the degree of the regurgitation could not be evaluated clearly due to the poor acoustic window. (Supplementary Video

2). An amorphous, mobile mass measuring 12x6 mm was observed on the ventricular face of the aortic valve (Supplementary Video 3-4).

Cardiac MRI was performed for quantification of aortic regurgitation. It confirmed severe, global left ventricular hypokinesia with an LVEF of 28%, increased indexed left ventricular volumes, biatrial dilatation, Sievert type 1 bicuspid aortic valve (Figure 2), and eccentric severe aortic regurgitation with a regurgitant fraction of 50%, mild mitral regurgitation and severe tricuspid regurgitation.

Considering Duke's criteria, the patient was diagnosed with infective endocarditis. The patient was consulted on infectious diseases for the appropriate antibiotic therapy. As the vegetation was causing severe aortic regurgitation and decompensated heart failure, cardiovascular surgeons assessed the patient too.

After the multidisciplinary evaluation of the patient, emergent aortic valve replacement was the recommended treatment. However, as the operative mortality risk was very high(EuroSCORE II over 40%), the patient and his family refused surgery. He was discharged from the hospital because of their own request. The patient, who continued to receive vancomycin treatment on dialysis days, experienced sudden cardiac death 4 months after discharge.

Table 1: Patient's laboratory findings

|	Value		Value
Hemoglobin (gr/dl)	8.6	CRP (mg/dl)	32.8
Hematocrit (%)	29.1	Procalsitonin (ng/ml)	1.5
WBC	6700	NT-proBNP (pg/ml)	38720
Platelet number	84000	Creatinin (mg/dl)	2.4

Figure 1: Continuous wave doppler image shows estimated pulmonary artery systolic pressure of 71 mmHg from severe tricuspid regurgitation.

Figure 2: Cardiac magnetic resonance image of Sievert type 1 bicuspid aortic valve.

Supplementary Video 1: Color doppler image of severe tricuspid regurgitation from apical 4 chamber window.

Supplementary Video 2: Color doppler image of eccentric aortic regurgitation from apical 5 chamber window. Due to jets eccentricity cardiac magnetic resonance imaging is performed for determining the severity of regurgitation.

Supplementary Video 3: Vegetation on ventricular side of aortic valve is shown in apical 5 chamber window. Patients left ventricle ejection fraction is %35.

Supplementary Video 4: Zoomed view of aortic valve vegetation.

DİSCUSSİON

Alagille syndrome was first described by Daniel Alagille in 1969. The incidence of Alagille syndrome has been reported as 1:30000 live births.[1] Various mutations in JAG1 and NOTCH2 genes have been observed in this syndrome.[2-3] These genes encode transmembrane ligands and receptors involved in the Notch signaling pathway. Intracellular proteins formed after proteolytic events in the Notch signaling pathway control gene transcription in the cell nucleus.[4] The diagnosis of Alagille syndrome can be made clinically or by demonstrating JAG1 and NOTCH2 gene mutations.

The most common cardiovascular abnormalities seen in Alagille syndrome are stenosis or hypoplasia of the pulmonary artery branches. Another frequently observed condition is tetralogy of Fallot. Apart from these pathologies, various anomalies such as atrial and ventricular septal defect, bicuspid aorta, and valvular aortic stenosis may also be seen[5] and observation of cardiac involvement in patients with Alagille syndrome significantly increases mortality.[6] Although there is no study conducted on the relationship between Alagille syndrome and pulmonary hypertension; the presence of pulmonary hypertension in this population is described in several case reports. According to the literature, it is seen that pulmonary hypertension generally develops in the setting of pulmonary stenosis in patients with Alagille syndrome.[7-8] However, recent studies have shown that pulmonary hypertension may develop as a result of disorders in the Notch gene pathway.[9-11] The presence of the NOTCH mutation seen in our patient may have contributed to the development of group 1 pulmonary hypertension without cardiac anomaly.

Infective endocarditis diagnosis is made by the modified Duke criteria.[12] The main topics of treatment can be summarized as antibiotic therapy and surgical treatment in people with appropriate indications. Particularly, indications for surgery in people with a diagnosis of infective endocarditis can be classified into three main groups;

development of heart failure, prevention of uncontrollable infections and embolisms. Emergent valve surgery is recommended with a class 1 indication in cases of acute severe mitral or aortic regurgitation and associated refractory pulmonary edema/cardiogenic shock in infective endocarditis cases. Cardiac surgery is urgently recommended for patients with severe aortic and mitral valve regurgitation and in the presence of signs of heart failure or echocardiographic findings showing poor hemodynamic tolerance.[13]

CONCLUSİONS

1. Cardiovascular involvement may be in Alagille syndrome.
2. Pulmonary hypertension in Alagille syndrome can be seen as associated with congenital defects such as pulmonary valve stenosis. In patients with Alagille syndrome who do not have congenital heart defects; pulmonary hypertension could be associated with NOTCH gene mutations

REFERENCES

1. Kamath BM, Bason L, Piccoli DA, I D Krantz, N B Spinner. Consequences of JAG1 mutations. J Med Genet. 2003;40(12):891–5.

2. L Li, I D Krantz, Y Deng, A Genin, A B Banta, C C Collins, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet. 1997;16(3):243-51.

3. Binita Maya Kamath, Robert C Bauer, Kathleen M Loomes, Grace Chao, Jennifer Gerfen, Anne Hutchinson, et al. NOTCH2 mutations in Alagille syndrome. J Med Genet. 2012;49(2):138-44.

4. Penton AL, Leonard LD, Spinner NB. Notch signaling in human development and disease. Semin Cell Dev Biol. 2012;23(4):450-7.

5. Doff B McElhinney, Ian D Krantz, Lynn Bason, David A Piccoli, Karan M Emerick, Nancy B Spinner,, et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation. 2002;106(20):2567-74.

6. K M Emerick, E B Rand, E Goldmuntz, I D Krantz, N B Spinner, D A Piccoli. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999;29(3):822-9.

7. McGahan RK, Tang JE, Iyer MH, Flores AS, Gorelik LA. Combined Liver Kidney Transplant in Adult Patient With Alagille Syndrome and Pulmonary Hypertension. Semin Cardiothorac Vasc Anesth. 2021;25(3):191-195.

8. Schulte-Bockholt A, Gebel M, Wittekind C, Burdelski M, Schmidt FW. [The Alagille syndrome in an adult]. Dtsch Med Wochenschr. 1990;115(34):1276-9.

9. Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med. 2009;15(11):1289-97.

10. Fouillade C, Monet-Leprêtre M, Baron-Menguy C, Joutel A. Notch signalling in smooth muscle cells during development and disease. Cardiovasc Res. 2012;95(2):138-46.

11. Liam A Hurst, Benjamin J Dunmore, Lu Long, Alexi Crosby, Rafia Al-Lamki, John Deighton, et al. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat Commun. 2017;8:14079.

12. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-8.

13. Gilbert Habib, Patrizio Lancellotti, Manuel J Antunes, Maria Grazia Bongiorni, Jean-Paul Casalta, Francesco Del Zotti, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J . 2015;36(44):3075-3128.